Kidney Week 2022: Exhibitor Spotlight Schedule
Thursday, November 3 - Saturday, November 5
Orange County Convention Center, West Building, Exhibit Hall D
Join your colleagues for the latest advances in nephrology practices, products, services, and technologies presented in two theaters on the exhibit hall floor. Seating is limited and available on a first-come, first-served basis to fully registered Kidney Week participants only. Exhibitor Spotlights are not CE (continuing education) activities.
All presentations include breakfast or lunch.
Thursday, November 3
10-10:45 a.m.
Jardiance® (empagliflozin) tablets: EMPEROR Clinical Trials Data Subgroup Analyses
Presented by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly
11:30 a.m.-12:15 p.m.
The Cardiorenal Connection: Providing Dual Cardiorenal Risk Reduction for Patients with CKD Associated with T2D
Presented by Bayer
12:30-1:15 p.m.
Are You Thinking Genetic? The Emerging Role of Genetics in CKD
Presented by Natera
1-1:45 p.m.
Perspectives on OmniGraf Use in Clinical Practice
Presented by Eurofins Transplant Diagnostics
Friday, November 4
10-10:45 a.m.
Understanding the Complexity of Patients with CKD: Implications for Management
Presented by AstraZeneca
11:30 a.m.-12:15 p.m.
New Data on an Autosomal Dominant Polycystic Kidney Disease (ADPKD) Treatment Option
Presented by Otsuka America Pharmaceutical, Inc.
12:30-1:15 p.m.
Developing Precision Medicines for Patients with IgAN
Presented by Chinook Therapeutics
1-1:45 p.m.
The Importance of Achieving a Complete Response in Lupus Nephritis
Presented by Aurinia Pharma U.S.
Saturday, November 5
10-10:45 a.m.
Physician-Patient Discussion: Does Patient Care Need to Evolve for Anemia of CKD?
Presented by GSK Medical Affairs
11:30 a.m.-12:15 p.m.
Surveillance Tools and Molecular Innovation for Transplant Patients
Presented by CareDx
12:30-1:15 p.m.
The Phosphorus Management Puzzle and Need for New Pieces: The Patient and Physician Perspective
Presented by Ardelyx
1-1:45 p.m.
First Steps for Females with GLA Variants Detected by Kidney Disease Panels: Actionable Findings
Presented by Sanofi
*Additional information available by clicking on title if provided by supporter.